Effectiveness and safety of red yeast rice predominated by monacolin K β-hydroxy acid form for hyperlipidemia treatment and management.

Autor:	Benjian C; Department of Medical, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China., Xiaodan H; Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China., Huiting P; First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China., Yishi LI; First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China., Yongtao C; Department of Mathematical & Computer Sciences, Indiana University of Pennsylvania, Indiana 15705, PA, USA., Huanlin WU; Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 350122, China., Danping XU; Department of Traditional Chinese Medicine, the Eighth Affiliated Hospital, SunYat-Sen University, Shenzhen 518033, China.
Jazyk:	angličtina
Zdroj:	Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan [J Tradit Chin Med] 2022 Apr; Vol. 42 (2), pp. 264-271.
DOI:	10.19852/j.cnki.jtcm.2022.02.007
Abstrakt:	Objective: To assess the lipid-lowering activity and safety of a dietary supplement containing monacolin K β-hydroxy acid form (MKA), Heye (), and Cangzhu (), compared to lifestyle modifications. Methods: Totally 117 subjects with moderate to severe dyslipidemia (according to Chinese guidelines) and low CV risk were randomly assigned into three treatment groups: lifestyle modification (LM), LM plus a low dosage of MKA, LM plus a high dosage of MKA, and treated for 60 d. The primary endpoint was the reduction of low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC). Safeties along with Traditional Chinese Medicine Syndromes were assessed through the study. Results: A low dosage of MKA along with lifestyle modifications caused a significant decrease in LDL-C by 15.6% on average (95% , 9.6% to 21%) with, a decrease in TC by 15.3% on average (95% CI, 9.26% to 21.4%), and a decrease in non-HDL-C by 35.4% (95% CI, 25.76% to 41.34%). Weak evidence of a reduction of triglycerides but an increment of HDL-C was observed in patients with severe hyperlipidemia. No severe adverse events occurred during the study. Conclusion: Our results confirm the LDL-C and TC lowering properties of MKA is clinically meaningful. It also produces a significant reduction of non-HDL-C, and slightly effects on TG and HDL-C as well.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu